Recerca

Àrea 5

Oncologia Molecular i Translacional

Articles de l'any 2010
Original

Originals publicats: 15

Factor d'impacte: mitjana: 8.77, total: 131.6

  • HER2 Silences Tumor Suppression in Breast Cancer Cells by Switching Expression of C/EBP beta Isoforms

    Arnal-Estape A, Tarragona M, Morales M, Guiu M, Nadal C, Massague J, Gomis RR
    CANCER RES. 2010; 70: 9927-9936. IF: 7.543

  • Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study

    Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeno M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J
    CLIN CANCER RES. 2010; 16: 2474-2482. IF: 6.747

  • Development of a new G-CSF product based on biosimilarity assessment

    Gascon P, Fuhr U, Sorgel F, Kinzig-Schippers M, Makhson A, Balser S, Einmahl S, Muenzberg M
    ANN ONCOL. 2010; 21: 1419-1429. IF: 5.647

  • Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study

    Martin-Broto J, Gutierrez A, Garcia-Del-Muro X, Lopez-Guerrero JA, Martinez-Trufero J, DeSande LM, Lainez N, Maurel J, DeJuan A, Losa F, Andres R, Casado A, Tejido PG, Blanco R, Carles J, Bellmunt J, Gomez-Espana A, Ramos R, Martinez-Serra J, Llombart-Bosch A, Poveda A
    ANN ONCOL. 2010; 21: 1552-1557. IF: 5.647

  • Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study

    Gascon P, Pirker R, DelMastro L, Durrwell L
    ANN ONCOL. 2010; 21: 2029-2039. IF: 5.647

Revisió

Revisions publicades: 3

Factor d'impacte: mitjana: 3.46, total: 10.37

  • Current perspectives of treatment of ductal carcinoma in situ

    Estevez LG, Alvarez I, Segui MA, Munoz M, Margeli M, Miro C, Rubio C, Lluch A, Tusquets I
    CANCER TREAT REV. 2010; 36: 507-517. IF: 5.295

  • Tyrosine Kinase Receptor Transactivation Associated to G Protein-Coupled Receptors

    Almendro V, Garcia-Recio S, Gascon P
    CURR DRUG TARGETS. 2010; 11: 1169-1180. IF: 3.932

Editorials

Editorials publicades: 1

Factor d'impacte: mitjana: 0.77, total: 0.77

  • Sentinel lymph node and neoadjuvant therapy in breast cancer

    Munoz M, Pahisa J, Caparros FX, Vidal-Sicart S
    REV ESP MED NUCL. 2010; 29: 319-320. IF: 0.765

Multicèntrics

Multicèntrics publicats: 3

Factor d'impacte: mitjana: 16.43, total: 49.3

  • Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer A Meta-analysis

    Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, VanCutsem E, Buyse M
    JAMA-J AM MED ASSOC. 2010; 303: 1729-1737. IF: 28.899

  • The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up

    Steinberg MH, Mccarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, Decastro L, Waclawiw MA
    AM J HEMATOL. 2010; 85: 403-408. IF: 2.61

Guies clíniques

Guies clínique publicades: 2

Factor d'impacte: mitjana: 1.23, total: 2.46

  • Recommendations for diagnosis, staging and treatment of pancreatic cancer (Part I). Grupo Español de Consenso en Cáncer de Páncreas.

    Navarro S, Vaquero E, Maurel J, Bombi JA, DeJuan C, Feliu J, Cruz LF, Gines A, Girela E, Rodriguez R, Sabater L
    MED CLIN-BARCELONA . 2010; 134: 643-655. IF: 1.231

  • Recommendations for diagnosis, staging and treatment of pancreatic cancer (Part II)

    Navarro S, Vaquero E, Maurel J, Bombi JA, DeJuan C, Feliu J, Cruz LF, Gines A, Girela E, Rodriguez R, Sabater L
    MED CLIN-BARCELONA. 2010; 134: 692-702. IF: 1.231

Més articles